Low-BMI, sub-160 lb, older, or side-effect-sensitive non-micro users often start at 0.3 mg, with the band still building to at least 1 mg before response is judged
The FDA has specifically warned that direct-to-consumer marketing cannot imply equivalence with FDA-approved drugs - including through references to "the same active ingredient." This regulatory position applies to every compounded semaglutide program in the market, not to Novi specifically
Compounding pharmacies don't follow the same manufacturing controls as FDA-approved medications like Zepbound
same separation logic | | Sublingual | Low | None beyond standard care | Limited clinical data on this route | | IV (600-2,400 mg/session) | Low-moderate | Baseline and periodic LFTs | Hepatic conjugation pathway overlap | Patients who are already taking both agents and have experienced no adverse effects can generally continue, provided their prescribing clinician is aware of both
The starting dose is 2.5 mg once a week
Coverage and prior authorization: The FDA has approved different GLP-1 drugs for specific uses